Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: July 2008
-
By Kevin E. Noonan — Last Friday, the European Patent Office revoked (in its entirety) European Patent No. EP 1 230 375, owned by Cancer Research Therapeutics Ltd. of Cambridge, UK and exclusively licensed to Alnylam Pharmaceuticals, Inc. The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis…
-
By Donald Zuhn — Earlier this month, Cellectis SA, based in Romainville Cedex, France, announced that it had reached an agreement with Regeneron Pharmaceuticals, Inc., of Tarrytown, NY, concerning the use of the French biotech company’s homologous recombination patent estate. Under the agreement, Regeneron would pay the French biotech company $12.45 million for…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Abbott Laboratories v. Dr. Reddy’s Laboratories, Inc. et al.3:08-cv-03390; filed July 8, 2008 in the District Court of New Jersey Infringement of…
-
July 16, 2008 – Patent Claim Construction Workshop (Law Seminars International) – Seattle, WA July 24-25, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – New York, NY August 11-12, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco,…
-
American Conference Institute (ACI) will be holding its Global Patent Litigation conference on October 7-8 in New York. The conference will allow attendees to: • Develop a strategic plan for where to file patents based on existing jurisdictional factors;• Ensure that patent rights will be enforced through a clear assessment of patent filing requirements in…
-
By Kevin E. Noonan — Insmed Inc. announced today that a just-completed clinical trial showed that its INS-19 product, a recombinant human granulocyte colony stimulating factor (G-CSF) was "bioequivalent" to Amgen’s FDA-approved Neupogen®, a product used for treating neutropenia, a blood deficiency disorder associated with, inter alia, chemotherapeutic drug treatment. One of the…
-
By Donald Zuhn — The Federal Circuit today affirmed a finding on summary judgment by the District Court for the Northern District of California that U.S. Patent No. 5,110,493, which is owned by Plaintiff-Appellee Roche Palo Alto LLC, is valid and infringed by Defendants-Appellants Apotex, Inc. and Apotex Corp. (Apotex). In affirming the…
-
By Donald Zuhn — Last month, we reported on a presentation that Dr. George Elliott, Group 1600 Director of the U.S. Patent and Trademark Office, gave at this year’s BIO International Convention (see "Docs at BIO: Representatives from JPO, EPO, SIPO, and USPTO Discuss Recent Developments in Japan, Europe, China, and the U.S."…
-
By Kevin E. Noonan — Two of the leaders among developing countries in challenging Western assumptions behind the TRIPS agreement and the WTO, Brazil and India, recently announced a further evolution of their national laws directed to implementing the provisions of that treaty. Brasil’s announcement concerns the administrative procedures governing the interaction between…
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) submitted an amicus brief today to the Court of Appeals for the Federal Circuit in the Amgen v. Hoffman-LaRoche case (see "Brief of Biotechnology Industry Organization as Amicus Curiae in Support of Appellee and Affirmance "). This case involves Roche’s Mircera® drug product,…
Patent Docs 